US20050025787A1 - Transformed bacteria producing CS6 antigens as vaccines - Google Patents

Transformed bacteria producing CS6 antigens as vaccines Download PDF

Info

Publication number
US20050025787A1
US20050025787A1 US10/754,641 US75464104A US2005025787A1 US 20050025787 A1 US20050025787 A1 US 20050025787A1 US 75464104 A US75464104 A US 75464104A US 2005025787 A1 US2005025787 A1 US 2005025787A1
Authority
US
United States
Prior art keywords
bacteria
sequence
proteins
css
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/754,641
Inventor
Marcia Wolf
Frederick Cassels
Edgar Boedeker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/754,641 priority Critical patent/US20050025787A1/en
Publication of US20050025787A1 publication Critical patent/US20050025787A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention is related to a CS6 antigen for use in vaccines to protect from pathological effects of enterotoxigenic E. coli.
  • CS6 is a component of CFA/IV (colonization factor antigen IV), one of three CFAs commonly found on enterotoxigenic Escherichia coli (ETEC).
  • ETEC enterotoxigenic Escherichia coli
  • the CS6 operon has much in common with fimbrial operons from E. coli, Salmonella, Yersinia, Klebsiella, Haemophilus , and Bordetella . All contain molecular chaperons and ushers and a number of structural subunits. This area contains two sequences homologous to insertion sequences, but no complete insertion sequences.
  • GC content 34%) and codon usage that is characteristic of E. coli genes that are expressed at low levels suggest the C ⁇ circumflex over ( ) ⁇ 6 genes may have originated in another species.
  • GC content of 35-45% is characteristic of Gram positive bacteria such as Staphylococcus, Streptococcus, Bacillus , and Lactobacillus .
  • Low GC content is common for virulence-associated genes of E. coli.
  • CS6 is unusual because it is expressed on bacteria grown on a variety of media, unlike other CFA's from ETEC that are only expressed on bacteria grown on CFA agar. This unusual regulation is not peculiar to strain E8775 because ETEC isolated in 1990 expressed CS6 when grown on L agar. Temperature regulation of CS6 expression is characteristic of other CFA's from ETEC and virulence genes in a variety of pathogenic bacteria.
  • CS6 has never been visualized by negative staining, electron microscopy using anti-CS6 sera and colloidal gold indicated that it is present on the surface of ETEC.
  • the apparent major protein associated with CS6 is approximately 16 kDa which is in the range of molecular weights typical for subunits for fimbriae and fibrillae.
  • CS6 from ETEC strain E10703 of serotype 0167:H5 has been cloned (Willshaw, et al., FEMS Microbio. Lett . 49: 473-478 (1988)). Only 3 kb of DNA was necessary for expression of CS6.
  • fimbriae that typically require approximately 9 kb of DNA and include genes for subunits as well as proteins for transport of subunits and synthesis and assembly on the bacterial surface.
  • Grewal teaches bacterial strains transformed with plasmids containing genes which encode CS6. However, that reference does not teach use of plasmids under the controls of a lac promoter and a CS6 promoter.
  • FIG. 1 shows the restriction sites and the location of the pertinent genes that make up the CS6 operon.
  • FIG. 2 shows derivation of the clone containing the kanamycin resistance gene.
  • the CS6 operon includes four genes which we designate cssA, cssB, cssC, and cssD. cssA and cssB encode the structural proteins of CS6. The CS6 operon has much in common with fimbrial operons from E.
  • plasmids containing all four genes are transformed into attenuated bacteria, which are then given by mouth to prevent morbidity arising from infection with E. coli.
  • CS6 has two major subunits; protein sequencing data demonstrates that CS6A and CS6B are both present.
  • the DNA sequence yields a mechanism for expression of similar amounts of the two proteins.
  • the CS6 operon contains DNA immediately downstream of cssB which can form a stem-loop with a stem rich in G and C which commonly act as transcription terminators. Termination at this site yields a transcript with cssA and cssB such that CssA and CssB proteins would be translated in equal amounts.
  • Fimbrial operons for Pap, K99, and K88 have stem loops immediately downstream of the genes for the major coding structural subunits. This has been offered as a mechanism for over expression of subunit genes relative to other genes in the operons. In the case of CS6, this would allow over expression of both CS6A and CS6B.
  • CssD belongs to the family of molecular ushers located in the outer membrane that accept subunits from the chaperone and escorts them to the bacterial surface. Apparently the entire cssD gene is not necessary for CS6 expression since CS6 was detected from clones carrying pDEP5 which only contains the N-terminal one-third of cssD. Klemm and Christiansen found that mutations in the usher for Type 1 fimbriae reduced fimbriation but 10% of the bacteria produced a few fimbriae ( Mol. Gen. Genet . 220:334-338).
  • the CS6 proteins are produced in the transformed bacteria and are present on the exterior surface of the bacteria. These proteins give rise to immunological response in the host. For immunization, the bacteria may be given either dead or alive. When attenuated bacteria have been transformed, the bacteria can be given live in mildly basic carriers. Economical and readily available carriers include carbonated water which may be flavored. The administration of the transformed bacteria in carbonated beverages is particularly useful, since the means necessary for administration is widely available.
  • the products are produced under the control of a lac promoter from pUC19.
  • a vector pM346 containing a kanamycin resistant gene makes it possible to provide products which are appropriate for use in humans.
  • the CS6 proteins may also be extracted from the supernatant of the culture containing the organisms which express the proteins. The proteins may then be administered orally.
  • the proteins may be formulated by means known in the art, including microencapsulation, coated capsules and liposomes. The proteins may be lyophilized before formulation.
  • the antibiotic resistance gene encodes resistance to kanamycin and was purchased from Pharmacia, Uppsala, Sweden (Kan R GenBlock®).
  • CS6 expression is regulated from its native promoter. That is demonstrated by retention of control by growth temperature and is consistent with the DNA sequence determined from the clone. A contribution of the lac promoter from pUC19 is undefined. The contribution of increased copy number of the plasmid is probably substantial.
  • E. coli HB101 was purchased from the American Type Culture Collection, Manassas Va. It is ATCC #33694 and batch #91-1. ( Escherichia coli ATCC 33694) Preceptrol® culture. D. Ish-Horowicz and J. F. Burke HB101 ⁇ H. Boyer. Genotype: F-leuB6 proA2 recA13 thi-1 ara-14 lac YlgalK2 xyl-5 mtl-1 rpsL20 supE44 hsdS20 (r-B m-B at least thi-hsd from Escherichia coli B). Produces isoprene ( Curr. Microbiol . 30:97-103, (1995), J. Mol. Biol. 41:459-472, (1969), Methods Enzymol. 68:245-267, (1979). Growth Conditions: Medium 1065 37° C.
  • the plasmid containing the CS6 genes, the pUC19 origin of replication, and the gene for kanamycin resistance was transferred into E. coli HB101 by transformation.
  • Transformants were selected by growth on L agar supplemented with 0.04% Xgal with 50 ⁇ gm per ml kanamycin sulfate and/or 50 ⁇ gm per ml ampicillin.
  • CS6 genes exist as an extrachromosomal plasmid of high (500-700) copy number.
  • the CS6 genes are present on a plasmid, not integrated into the chromosome.
  • the plasmid has been isolated from the strain and examined by agarose gel electrophoresis.
  • Plasmid DNA from M56 was isolated, partially digested with restriction enzyme HindIII, and ligated to pUC19 that had been digested with HindIII.
  • the ligation mixture was transformed into DH5 ⁇ and plated onto L agar supplemented with ampicillin and X-gal. White (lac ⁇ ) colonies were picked to CFA plates supplemented with ampicillin and tested for CS6 expression.
  • the protein sequence of the N-terminus of CS6 was determined from strains E8775 and from M233, the large clone derived from E8775.
  • the 16 kDa proteins recovered from heat, saline extracts, and ammonium sulfate precipitation of M233 yielded two amino acids at each position (except cycle 12) indicating that two proteins were present. From the strength of the two signals, a probable primary sequence and a probable secondary sequence call was made for each of fifteen cycles. Quantitative analysis of the peak areas indicated that the molar ratio of the primary sequence (CS6A) to secondary sequence (CS6B) was approximately 3:1. The presence of the same two proteins was evident from strain E8775 grown on CFA agar and on L agar.
  • the DNA sequence of the DNA inserted into pUC19 in clone M285 was determined. Wim Gaastra's group in the Netherlands independently determined the DNA sequence of CS6 genes from ETEC strain E10703. The DNA sequences are available from Genebank accession numbers U04846 and U04844, respectively. A stretch of DNA of 4,219 base pairs was 98% identical. The DNA sequences diverge abruptly on both sides of the common region, defining the limits of the CS6 genes. Four open reading frames were detected within the common area. These were designated cssA, cssB, cssC, and cssD.
  • the four open reading frames are preceded by consensus sequences for binding RNA polymerase and ribosomes.
  • the first open reading frame, cssA was identified as the gene for the CS6 structural protein designated as the primary protein based on the amino acid N-terminal sequence. The deduced molecular weight agrees with that previously determined from SDS PAGE. cssA includes a signal sequence that is typical for many exported proteins. Eleven of 136 residues differ between the deduced CssA proteins from E8775 and from E10704.
  • a region of dyad symmetry is present 6 bases downstream from cssB in both clones.
  • the sequence is GGCCGCA TTAT TGCGGCC (SEQ ID NO:2) in E8775 ETEC and GGCCGCA TTATTGAT TGCGGCC (SEQ ID NO:3) in E10703.
  • Underlined bases form the G-C rich stem.
  • the calculated free energy value of these structures is ⁇ 14.8 kcal. Such structures are often found in fimbrial operons after the genes encoding structural proteins.
  • cssC begins 48 bases downstream from cssB. It has a typical signal sequence.
  • the deduced proteins from both clones have 212 residues with 7 differences.
  • a search of protein databases indicated CssC is homologous to chaperone proteins necessary for expression of a number of fimbriae.
  • the structure of PapD, the chaperone protein for Pap fimbriae has been solved by X-ray crystallography and regions important for conserving the structural domains have been identified. CssC conforms to this consensus.
  • a region of dyad symmetry is present 347 base pairs into the cssD gene in both clones.
  • the calculated free energy value of these structures is ⁇ 7.2 kcal.
  • the plasmid from strain M285 was transformed into E. coli HB101 purchased from ATCC.
  • the resulting strain was named M295.
  • Expression of CS6 from M295 was achieved from small-scale fermentation. For production for human use, it was desirable to add a gene for resistance to kanamycin as the selectable marker. To that end, a vector was constructed based on pUC19 but with a gene for kanamycin resistance in place of the gene for ampicillin resistance.
  • the CS6 genes from the pUC19 clone were subcloned into the new vector and transformed into E. coli HB101.
  • Vector pM323 was constructed as follows.
  • the kanamycin resistance gene was purchased from Pharmacia, Uppsala, Sweden (Kan R GenBlock®) and inserted into a cloning vector by Dr. David Lanar at WRAIR.
  • DNA including the gene was amplified by PCR using the plasmid from Dr. Lanar as template and primers flanking the multiple cloning site.
  • a product of the desired size (1,580 bp) was obtained, but with much template present.
  • a second PCR reaction was performed, this time with a small amount of the first PCR reaction as template. This product was confirmed by agarose gel electrophoresis, then digested with restriction enzyme HincII to remove unwanted restriction enzyme recognition sites.
  • This product was ligated to pUC19 digested with Sspl.
  • the ligation mix was transformed into E. coli DH5 ⁇ and plated on L agar plates supplemented with kanamycin and Xgal.
  • Isolate M318 had the desired phenotype of resistance to kanamycin and ampicillin with lacZ′ intact.
  • the gene for ampicillin resistance was removed to make a smaller vector. This was achieved by designing and synthesizing 2 oligonucleotides to amplify just the portion of pM318 with the gene for kanamycin resistance, the lacZ′ gene carrying the multiple cloning site, and the origin of replication. PCR was performed, the product ligated then transformed into E.
  • Isolate M323 had the desired phenotype of resistance to kanamycin, sensitivity to ampicillin, and intact lacZ′. Restriction digest patterns confirmed the plasmid was a derivative of pUC19 with the gene for kanamycin resistance in place of the gene for ampicillin resistance.
  • the CS6 genes were cloned into vector pM323 from pM285.
  • pM323 and pM285 were digested with restriction enzyme SstI, ligated, and transformed into E. coli DH5 ⁇ with selection on L agar plates supplemented with kanamycin and Xgal.
  • Isolate M334 was determined to express CS6. Plasmid analysis revealed M334 carried the CS6 genes and 2 copies of the vector. An attempt was made to remove one copy of vector and at the same time move the clone into HB101, the desired host strain for fermentation.
  • Isolate M340 was determined to express CS6 and retained 2 copies of the vector. An isolated colony of M340 was shown to produce high amounts of CS6 and was saved as M346.
  • E. coli E8775 which was originally isolated from samples from Bangladesh.
  • E. coli M56 which contains a 61-megadalton plasmid from E8775 Tox ⁇ and expresses CS6 has been described.
  • the host for cloning was E. coli DH5 ⁇ which was purchased from Bethesda Research Laboratories, Inc., Gaithersburg, Md.
  • the host for plasmids used for production of heat, saline extracts was HB101 ( EMBO J . 4:3887-3893 (1985)).
  • Clones from E8775 were routinely grown in L broth. Antibiotics were added to L broth supplemented with agar as follows. Ampicillin was added, when appropriate, at 50 ⁇ g/ml. Chloramphenicol was used at 30 ⁇ g/ml. X-Gal (5-bromo-4-chloro-3-indolyl ⁇ -D-galactopyranoside, Sigma) was added at 0.004%. CFA plates were prepared as previously described ( Infect. Immun . 57:164-173 (1989)).
  • CS6 expression by bacterial colonies was detected after transfer to nitrocellulose and treatment as described by Mierendorf ( Methods Enzymol. Methods Enzymol . 152:458-469 (1987)).
  • Primary antisera was specific for CS6 and was raised in rabbits and absorbed as previously described ( Infect. Immun . 57:164-173 (1989)), except that rabbits were inoculated intravenously with live bacteria suspended in normal saline.
  • Secondary antibody was peroxidase-conjugated goat anti-rabbit IgG (Cappel Laboratories, Cochranville Pa.) and detection was by TMB Substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.).
  • CS6 Positive identification of CS6 was by western blots of heat, saline extracts. Heat, saline extracts were prepared from bacteria grown on the indicated media as described ( Infect. Immun . 27:657-666 (1980)). Proteins were separated on precast 16% Tricine sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE, Novex Novel Experimental Technology, San Diego Calif.) and transferred to nitrocellulose. Blots were handled as described above for colony blots.
  • PVDF polyvinylidene difluoride
  • DNA sequencing DNA sequencing of the clones derived from E8775 was performed using the Model 373A DNA sequencing system from Applied Biosystems, Inc, Foster City, Calif. Reactions were performed using the dideoxy method with fluorescent dye-labeled terminators, double-stranded templates, oligonucleotide primers, and AmpliTaq DNA polymerase following the manufacturer's protocol. Appropriate oligonucleotide primers were synthesized using a Model 391 DNA Synthesizer (Applied Biosystems, Inc, Foster City, Calif.).
  • Plasmids were purified for use as templates by a slight modification of the alkaline lysis method and cesium chloride density gradient centrifugation described by Maniatis (M OLECULAR C LONING : A L ABORATORY M ANUAL Cold Spring Harbor Laboratory, Cold Spring Harbor (1982)). Plasmids were recovered by dialysis followed by multiple ethanol precipitations to remove residual salt. Sequence analysis was performed using software developed by the University of Wisconsin Genetics Computer Group ( Nucleic Acids Res . 12:387-395 (1984)).
  • CS6 genes cloned from ETEC strain E8775 into PUC19 were obtained from a partial digest of the 61-megadalton plasmid from E. coli M56. It was a spontaneous deletion of a larger clone. The insert in M233 was approximately 24 kb. Subclones were obtained by digestion with various enzymes and a subclone containing 4.9 kb from the Hindlll site to Kpnl was found that expressed CS6. This clone was designated M285. Expression of CS6 was verified by transferring plasmids into E. coli HB 101 and detecting CS6 in heat, saline extracts.
  • CS6 The cloned CS6 is expressed under the same conditions as CS6 from the native 61-megadalton plasmid (Table 1). CS6 was detected in western blots of heat, saline extracts of bacteria grown on CFA, L agar or MacConkey agar. CS6 was not expressed on bacteria grown at 17° C. TABLE 1 Regulation of CS6 Expression Strain: M287 M56 E8775 HB101 Plasmid: pM285 native native none Chromosome: HB101 HB101 native HB101 Media — — — — CFA 37° C. + + + ⁇ CFA 17° C. ⁇ ⁇ ⁇ L agar + + + ⁇ MacConkey + + + + ⁇
  • N-terminal sequence of CS6 The protein sequence of the N-terminus of CS6 was determined from strains E8775 and from M233, the large clone derived from E8775. The 16 kDa proteins recovered from heat, saline extracts, and ammonium sulfate precipitation of M233 yielded two amino acids at each position (except cycle 12) indicating that two proteins were present. From the strength of the two signals, a probable primary sequence and a probable secondary sequence call was made for each of fifteen cycles. Quantitative analysis of the peak areas indicated that the molar ratio of the primary sequence (CS6A) to secondary sequence (CS6B) was approximately 3:1. The presence of the same two proteins was evident from strain E8775 grown on CFA agar and on L agar.
  • DNA sequence of CS6 operons The sequences of DNA cloned from E8775 (in M285) were determined. They are available from Genebank accession number U04846. The DNA sequence, when compared with sequences from another strain, were found to diverge abruptly on both sides of the common area. Four open reading frames were detected. These were designated cssA, cssB, cssC, and cssD for CS6.
  • the GC content of the DNA is 34% and the codon usage is in the range found for Escherichia coli genes that are expressed at low or very low levels as defined by Osawa et al. ( Prokaryotic Genetic Code. Experentia 46:1097-1106 (1990)).
  • CS6 structural genes Genes encoding CS6 structural genes. The four open reading frames are preceded by consensus sequences for binding RNA polymerase and ribosomes. DNA and deduced amino acid sequence of css>A, a CS6 structural protein. The DNA sequence of the entire operon is available from Genebank accession number U04844. The deduced amino acid sequence from E8775 is given. The arrow indicates the site of cleavage of the signal peptide.
  • the protein sequence is associated with the sequence for the second construct: ⁇ 3S ⁇ 1C RBS TTGACACATTACGAATCTTATGTATACAATAAAAATGATTATAGCAATATTAATGGTGTTAT ATGAAGAAAACAATTGGTTTAATTCTAATTCTTGCTTCATTCCCCAGCCATGCCAGAACA M K K T I G L I L I L A S F G S H A R T 2 ⁇ GAAATAGCGACTAAAAACTTCCCAGTATCAACGACTATTTCAAAAAGTTTTTTTGCACCT E I A T K N P P V S T T I S K 5 F F A P 22 GAACCACGAATACAGCCTTCTTTTGGTGAAAATGTTGGAAAGGAAGGAGCTTTATTATTT E P R I Q P S F G E N V G K E G A L L F 42 AGTGTGAACTTAACTGTTCCTGAAAATGTATCCCAGGTAACGGTCTACCCTGTTTATCAT S V N L T V P E N V S Q V T V Y P V Y D
  • cssA The first open reading frame, cssA was identified as the gene for the CS6 structural protein CS6A designated as the primary protein based on the amino acid N-terminal sequence. cssA includes a signal sequence that is typical for many exported proteins.
  • the deduced CssA protein from E8775 has 136 residues, as shown above and in Table 2. The molecular weight agrees with that previously determined from SDS PAGE. No homologous proteins were found by searching the protein databases, but conserved residues are present near the C-terminus and this is typical of fimbrial subunits that are carried across the periplasm by chaperons.
  • cssB begins 17 bases downstream from cssA. There is a typical signal sequence. cssB was identified as the gene for the CS6 structural protein CS6B designated as the secondary protein based on the amino acid N-terminal sequence. The C-terminus matches the consensus typical of fimbrial subunits. The sequence from E8775 is given. The arrow indicates the site of cleavage of the signal peptide.
  • a region of dyad symmetry is present 6 bases downstream from cssB in both clones.
  • the sequence is GGCCGCA TTAT TGCGGCC (SEQ ID NO:2) in E8775 ETEC. Underlined bases form the GC rich stem.
  • CssC begins 48 bases downstream from cssB. It has a typical signal sequence.
  • the deduced proteins from both clones have 212 residues with 7 differences.
  • a search of protein databases indicated CssC is homologous to chaperone proteins necessary for expression of Pap, CS3, K88, K99, CS31A, S, and Type 1 fimbriae of E.
  • cssD begins 14 bases upstream of the end of cssC.
  • the deduced protein from cssD is homologous to molecular ushers found in operons of Pap, CS3, K88, K99 and Type 1 fimbriae of E. coli and SEF14 of Salmonella enteritidis , F1 of Yersinia pestis , and Type 3 of Klebsiella pneumoniae .
  • CssD and the other proteins are only around 30% identical and around 50% similar. Asterisks above the CssD sequences indicates amino acids conserved relative to molecular ushers.
  • CssD has 4 cysteines (residues 91, 112, and two near the C-terminus) which are conserved in all ushers.
  • a region of dyad symmetry is present 347 base pairs into the cssD gene in both clones.
  • the calculated free energy value of these structures is ⁇ 7.2 kcal.
  • DNA flanking the CS6 genes When compared with another strain, the DNA sequences of the two clones diverge immediately Idownstream of cssD and 96 bases upstream of cssA.
  • the non-homologous flanking regions have homology with five distinct insertion sequences.
  • the homologies include 3% to 32% of each insertion sequence but not entire insertion sequences.
  • the homology of and Iso-ISI in E8775 continues beyond the clones we have sequenced and may be a complete insertion sequences in the native plasmids.
  • bacteria transformed with plasmids which express the CS6-A and CS6-B proteins may be administered by mouth. If the transformed bacteria are attenuated strains, they may be delivered live. It is also possible to administer killed bacteria. Carbonated beverages such as carbonated water are particularly useful as carriers which are inexpensive. When the bacteria are administered in a carrier wherein the pH is not over 7, an antacid may be given with the bacteria.
  • the CS6 A and CS6 B proteins may also be at least partially purified and administered by mouth by means usually used in the art to deliver antigens to the intestinal tract, including in protected forms such as liposomes, microcrystals, microdroplets, as microencapsulated formulations or as enterically coated capsules.

Abstract

Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. patent application Ser. No. 09/479,877, filed Jan. 10, 2000, allowed, which is a continuation of U.S. patent application Ser. No. 08/788,145, filed Jan. 24, 1997, abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 08/243,482, filed May 13, 1994, abandoned.
    • ACKNOWLEDGMENT OF GOVERNMENT SUPPORT
  • This invention was made by employees of the United States Army. The government has rights in the invention.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention is related to a CS6 antigen for use in vaccines to protect from pathological effects of enterotoxigenic E. coli.
  • 2. Description of the Related Art
  • CS6 is a component of CFA/IV (colonization factor antigen IV), one of three CFAs commonly found on enterotoxigenic Escherichia coli (ETEC). A recent study showed CS6 on 31% of ETEC isolated from soldiers in the Middle East. Other CFAs and similar proteins found on the surface of ETEC function as adhesins to attach bacteria to intestinal epithelial cells. Attached bacteria can then deliver their toxin(s) to the target cells. It has never been proved that CS6 is an adhesin for human tissue (Knutton, S., M. M. McConnell, B. Rowe, and A. S. McNeish, “Adhesion and Ultrastructural Properties of Human Enterotoxigenic Escherichia coli Producing Colonization Factor Antigens III and IV”, Infect. Immun. 57:3364-3371 (1989)), but a study in rabbits indicated CS6 is a colonization factor.
  • The CS6 operon has much in common with fimbrial operons from E. coli, Salmonella, Yersinia, Klebsiella, Haemophilus, and Bordetella. All contain molecular chaperons and ushers and a number of structural subunits. This area contains two sequences homologous to insertion sequences, but no complete insertion sequences.
  • The low GC content (34%) and codon usage that is characteristic of E. coli genes that are expressed at low levels suggest the C{circumflex over ( )}6 genes may have originated in another species. GC content of 35-45% is characteristic of Gram positive bacteria such as Staphylococcus, Streptococcus, Bacillus, and Lactobacillus. Low GC content is common for virulence-associated genes of E. coli.
  • CS6 is unusual because it is expressed on bacteria grown on a variety of media, unlike other CFA's from ETEC that are only expressed on bacteria grown on CFA agar. This unusual regulation is not peculiar to strain E8775 because ETEC isolated in 1990 expressed CS6 when grown on L agar. Temperature regulation of CS6 expression is characteristic of other CFA's from ETEC and virulence genes in a variety of pathogenic bacteria.
  • Although CS6 has never been visualized by negative staining, electron microscopy using anti-CS6 sera and colloidal gold indicated that it is present on the surface of ETEC. The apparent major protein associated with CS6 is approximately 16 kDa which is in the range of molecular weights typical for subunits for fimbriae and fibrillae. CS6 from ETEC strain E10703 of serotype 0167:H5 has been cloned (Willshaw, et al., FEMS Microbio. Lett. 49: 473-478 (1988)). Only 3 kb of DNA was necessary for expression of CS6.
  • That is in contrast to fimbriae that typically require approximately 9 kb of DNA and include genes for subunits as well as proteins for transport of subunits and synthesis and assembly on the bacterial surface.
  • Grewal teaches bacterial strains transformed with plasmids containing genes which encode CS6. However, that reference does not teach use of plasmids under the controls of a lac promoter and a CS6 promoter.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the restriction sites and the location of the pertinent genes that make up the CS6 operon.
  • FIG. 2 shows derivation of the clone containing the kanamycin resistance gene.
    • DETAILED DESCRIPTION OF THE INVENTION
  • It is the purpose of this invention to provide structural proteins which will act as antigens to stimulate protective antibodies against enterotoxigenic Escherichia coli. Particularly important are proteins having the antigenic properties of the proteins encoded by the cssA and cssB genes. Constructs may be prepared which encode either one or both of the proteins. However, both proteins would be needed to provide desirable protection. The CS6 operon includes four genes which we designate cssA, cssB, cssC, and cssD. cssA and cssB encode the structural proteins of CS6. The CS6 operon has much in common with fimbrial operons from E. coli, Salmonella, Yersinia, Klebsiella, Haemophilus, and Bordetella. All contain molecular chaperons and ushers and a number of structural subunits. In a preferred embodiment, plasmids containing all four genes are transformed into attenuated bacteria, which are then given by mouth to prevent morbidity arising from infection with E. coli.
  • CS6 has two major subunits; protein sequencing data demonstrates that CS6A and CS6B are both present. The DNA sequence yields a mechanism for expression of similar amounts of the two proteins. The CS6 operon contains DNA immediately downstream of cssB which can form a stem-loop with a stem rich in G and C which commonly act as transcription terminators. Termination at this site yields a transcript with cssA and cssB such that CssA and CssB proteins would be translated in equal amounts. Fimbrial operons for Pap, K99, and K88 have stem loops immediately downstream of the genes for the major coding structural subunits. This has been offered as a mechanism for over expression of subunit genes relative to other genes in the operons. In the case of CS6, this would allow over expression of both CS6A and CS6B.
  • The occurrence of two major structural proteins is unusual because fimbriae have a single major subunit and a number of minor subunits. CS3, which has been designated fibrillar rather than fimbrial, is an exception to this generality because it has 2 subunits. CssD belongs to the family of molecular ushers located in the outer membrane that accept subunits from the chaperone and escorts them to the bacterial surface. Apparently the entire cssD gene is not necessary for CS6 expression since CS6 was detected from clones carrying pDEP5 which only contains the N-terminal one-third of cssD. Klemm and Christiansen found that mutations in the usher for Type 1 fimbriae reduced fimbriation but 10% of the bacteria produced a few fimbriae (Mol. Gen. Genet. 220:334-338).
  • The CS6 proteins are produced in the transformed bacteria and are present on the exterior surface of the bacteria. These proteins give rise to immunological response in the host. For immunization, the bacteria may be given either dead or alive. When attenuated bacteria have been transformed, the bacteria can be given live in mildly basic carriers. Economical and readily available carriers include carbonated water which may be flavored. The administration of the transformed bacteria in carbonated beverages is particularly useful, since the means necessary for administration is widely available.
  • In a preferred embodiment, the products are produced under the control of a lac promoter from pUC19. In the preferred embodiment, a vector pM346 containing a kanamycin resistant gene makes it possible to provide products which are appropriate for use in humans.
  • The CS6 proteins may also be extracted from the supernatant of the culture containing the organisms which express the proteins. The proteins may then be administered orally. The proteins may be formulated by means known in the art, including microencapsulation, coated capsules and liposomes. The proteins may be lyophilized before formulation.
    • Materials and Methods
  • A. Source of Nucleic Acid
  • The genes for CS6 expression were from enterotoxigenic Escherichia coli (ETEC) strain E8775 tox− of serotype 025:H42 which was a gift from Alejandro Cravioto. E8775 tox− is a derivative of E. coli strain E8775 which was originally isolated from Bangladesh. DH5α which was purchased from Bethesda Research Laboratories, Inc., Gaithersburg, Md. pUC19 was originally purchased from P-L Biochem.
  • The antibiotic resistance gene encodes resistance to kanamycin and was purchased from Pharmacia, Uppsala, Sweden (KanR GenBlock®).
  • CS6 expression is regulated from its native promoter. That is demonstrated by retention of control by growth temperature and is consistent with the DNA sequence determined from the clone. A contribution of the lac promoter from pUC19 is undefined. The contribution of increased copy number of the plasmid is probably substantial.
  • The nucleotide sequence containing the coding region was determined to be as constructed containing the kanamycin resistance gene was as follows:
    1 AAGCTTGTAA CCAGTTGATA AAAATATATC ACGCTGGGAA TGACGTGATG (SEQ ID NO: 1)
    51 TATATACGGA GCAGCTATGT CGGAACAGAT ATTTTCCTAT CGGTATGCGT
    101 TGTGAGTAAG CGTAAAGCCA ATGCTGTCTG TAACTCCTGA TCCTTGCAGA
    151 CTAAATTAGA GCTCCTTCTA AATTAGACGG ATGGATAAAC CTACAGACTG
    201 GCGCTCTGGG TCTCGCCGGA TATTTTCTAA TGAATTTAAG CTTCATATGG
    251 TTGAACTGGC TTCGAAACCA AATGCCAATG TCGCACAACT GGCTCGGGAA
    301 CATGGCGTTG ATAACAACCT GATTTTTAAA TAGCTACGCC TCTGGCAAAG
    351 AGAAGGACGT ATTTCTCGTA GAATGCCTCC AACTATTGTA GGCCCTACAG
    401 TACCACTGAG GTAGCCTGAA TTTAAAGCCG AAGCGGTCAG AACTGTTCTT
    451 GGTGTGAACG TAGCACTCAC CAATAAAAGC ATCAATACGG TGCTCTGTTG
    501 ACACATTACG AATGTTATGT ATACAATAAA AATGATTATA GCAATATTAA
    551 TGGTGTTATA TGAAGAAAAC AATTGGTTTA ATTCTAATTC TTGCTTCATT
    601 CGGCAGCCAT GCCAGAACAG AAATAGCCAC TAAAAACTTC CCAGTATCAA
    651 CGACTATTTC AAAAAGTTTT TTTGCACCTG AACCACGAAT ACAGCCTTCT
    701 TTTGGTGAAA ATGTTGGAAA GGAAGGAGCT TTATTATTTA GTGTGAACTT
    751 AACTGTTCCT GAAAATGTAT CCCAGGTAAC GGTCTACCCT GTTTATGATG
    801 AAGATTATGG GTTAGGACGA CTAGTAAATA CCGCTGATGC TTCCCAATCA
    851 ATAATCTACC AGATTGTTGA TGAGAAAGGG AAAAAAATGT TAAAAGATCA
    901 TGGTGCAGAG GTTACACCTA ATCAACAAAT AACTTTTAAA GCGCTGAATT
    951 ATACTAGCGG GGAAAAAAAA ATATCTCCTG GAATATATAA CGATCAGGTT
    1001 ATGGTTGGTT ACTATGTAAA CTAAATACTG GAAGTATGAT TATGTTGAAA
    1051 AAAATTATTT CGGCTATTGC ATTAATTGCA GGAACTTCCG GAGTGGTAAA
    1101 TGCAGGAAAC TGGCAATATA AATCTCTGGA TGTAAATGTA AATATTGAGC
    1151 AAAATTTTAT TCCAGATATT GATTCCGCTG TTCGTATAAT ACCTGTTAAT
    1201 TACGATTCGG ACCCGAAACT GGATTCACAG TTATATACCG TTGAGATGAC
    1251 GATCCCTGCA GGTGTAAGCG CAGTTAAAAT CGCACCAACA GATAGTCTGA
    1301 CATCTTCTGG ACAGCAGATC GGAAAGCTGG TTAATGTAAA CAATCCAGAT
    1351 CAAAATATGA ATTATTATAT CAGAAAGGAT TCTGGCGCTG GTAACTTTAT
    1401 GGCACGACAA AAAGGATCCT TTCCTGTCAA AGAGAATACG TCATACACAT
    1451 TCTCAGCAAT TTATACTGGT GGCGAATACC CTAATAGCGG ATATTCGTCT
    1501 GGTACTTATG CAGGAAATTT GACTGTATCA TTTTACAGCA ATTAAAAAAA
    1551 GGCCGCATTA TTGCGGCCAT TGACGATACT GCTAGGCAAA AATATGAAAT
    1601 CAAAGTTAAT TATACTATTG ACGTTAGTGC CATTTTCATC TTTTTCAACA
    1651 GGAAATAATT TTGAAATAAA TAAGACACGA GTAATTTACT CTGACAGCAC
    1701 ACCATCAGTT CAAATATCAA ATAATAAAGC ATATCCTTTA ATTATTCAAA
    1751 GCAATGTATG GGATGAAAGC AATAATAAAA ATCATGACTT TATAGCAACA
    1801 CCACCGATTT TTAAAATGGA AAGTGAAAGT CGGAATATAA TAAAAATAAT
    1851 TAAAACAACT ATTAATTTGC CGGACTCTCA GGAAAGTATG AGATGGTTAT
    1901 GTATTGAATC AATGCCACCA ATAGAAAAAA GTACTAAAAT AAACAGAAAA
    1951 GAAGGAAGGA CAGACAGTAT TAATATCAGC ATTCGGGGGT GCATTAAACT
    2001 GATATATCGA CCTGCCAGTG TTCCGTCTCC TGTTTTTAAT AATATAGTAG
    2051 AAAAATTAAA ATGGCATAAA AATGGAAAGT ATCTTGTATT AAAAAATAAT
    2101 ACACCCTATT ACATTAGCTT TTCTGAGGTT TTTTTTGATT CAGATAAAGT
    2151 AAACAATGCA AAAGATATTT TATATGTAAA ACCATACTCA GAGAAGAAAA
    2201 TAGATATCAG CAACAGAATA ATAAAAAAAA TCAAATGGGC TATGATTGAT
    2251 GATGCTGGCG CAAAAACAAA ACTTTATGAA TCAATTTTAT AAAAAATCTC
    2301 ATTACAGTAT ACAAAAACAT CAGATTACAG GCTTGCTTTT TTTGCTATTT
    2351 ATATATCCTT TCTCAACCTC ATATGGAAAT GAACAATTTA GTTTTGACTC
    2401 ACGATTCCTA CCATCAGGTT ATAATTACTC TTTAAATAGT AACTTACCTC
    2451 CTGAAGGTGA GTATCTGGTT GATATTTATA TTAACAAAAT AAAAAAGGAG
    2501 TCCGCGATTA TTCCTTTTTA TATAAAAGGA AATAAACTTG TACCATGTTT
    2551 ATCAAAAGAA AAAATTTCAT CTTTGGGTAT CAACATTAAT AATAACGACA
    2601 ACACAGAGTG TGTAGAAACA AGTAAGGCAG GTATTAGTAA TATCAGCTTT
    2651 GAGTTTAGCT CTCTTCGTTT GTTTATTGCT GTACCGAAAA ATCTTCTGTC
    2701 TGAGATTGAT AAAATATCAT CAAAGGATAT AGATAACGGG ATTCATGCTT
    2751 TATTTTTTAA TTATCAAGTA AATACAAGGC TAGCCAATAA TAAAAATCGT
    2801 TATGATTACA TTTCTGTTTC ACCAAATATA AATTATTTTT CATGGCGGTT
    2851 GCGTAATCTT TTTGAATTTA ACCAAAACAA CGATGAAAAA ACATGGGAAA
    2901 GAAACTACAC TTATCTAGAA AAAAGTTTTT ATGATAAAAA GCTAAACTTA
    2951 GTCGTTGGTG AAAGTTATAC GAATTCAAAT GTTTATAATA ACTACTCTTT
    3001 TACTGGTATT TCAGTTTCTA CAGATACAGA TATGTATACG CCAAGTGAAA
    3051 TCGATTATAC ACCAGAAATT CATGGAGTGG CTGATTCAGA CTCTCAGATT
    3101 ATTGTCAGGC AAGGCAACAC CATTATCATT AATGAAAGTG TTCCAGCCGG
    3151 ACCGTTCTCA TTTCCAATAA CCAATCTCAT GTATACTGGG GGGCAACTTA
    3201 ATGTGGAGAT AACAGATATT TATGGAAATA AAAAACAATA TACTGTCAAT
    3251 AATTCCTCTC TTCCTGTTAT GAGAAAAGCG GGACTAATGG TATATAATTT
    3301 TATATCTGGG AAATTAACAA AAAAAAATAG TGAGGATGGT GATTTTTTTA
    3351 CTCAAGGTGA TATTAACTAC GGTACTCACT ATAACAGCAC ACTATTCGGT
    3401 GGATATCAGT TTAGTAAAAA TTATTTTAAC TTATCTACTG GTATAGGCAC
    3451 TGATCTGGGA TTTTCTGGAG CATGGCTACT ACACGTTAGC AGAAGTAATT
    3501 TTAAGAATAA AAATGGATAT AATATTAATC TACAACAAAA CACTCAGTTA
    3551 AGACCATTCA ATGCCGGGGT TAATTTCGAT TACGCATACA GAAAAAAAAG
    3601 GTATGTGGAA CTTTCCGACA TTGGCTGGCA TGGTAATTTA TATAATCAAC
    3651 TTAAAAATAG TTTTTCTTTA TCCTTGTCAA AATCATTGAA TAAATACGGA
    3701 AATTTCTCAC TTGATTATAA CAAAATGAAA TACTGGGATA ATGCGTATGA
    3751 TAGTAACTCA ATGTCGATTC GTTATTTTTT TAAATTCATG CGAGCAATGA
    3801 TTACAACAAA TTGTTCTTTA AATAAATATC AATCTTATGA AAAAAAAGAT
    3851 AAAAGATTTA GTATTAATAT ATCATTGCCT TTAACCAAAG ATTACGGGCA
    3901 CATATCTTCA AACTATTCAT TTTCCAATGC AAATACAGGA ACGGCAACCA
    3951 GTTCTGTAGG CTTAAACGGT AGTTTTTTTA ATGACGCAAG ATTAAACTGG
    4001 AACATTCAGC AGAACAGAAC GACCCGTAAC AATGGATATA CTGATAATAC
    4051 CAGTTACATA GCAACCAGCT ATGCCTCTCC CTATGGCGTT TTTACTGGTT
    4101 CATATTCAGG ATCGAACAAG TATTCAAGCC AGTTTTATTC TGCATCGGGA
    4151 GGTATTGTTT TGCATAGCGA TGGCGTAGCT TTTACTCAAA AAGCCGGAGA
    4201 TACCTCTGCT CTTGTCCGTA TTGATAATAT TTCTGATATA AAAATTGGTA
    4251 ACACTCCTGG TGTTTATACT GGGTATAATG GTTTTGCTTT AATTCCTCAT
    4301 CTTCAGCCGT TCAAAAAAAA CACCATTTTA ATTAATGATA AAGGAATTCC
    4351 AGACGGTATT ACTCTTGCTA ATATAAAAAA ACAAGTTATC CCATCACGAG
    4401 GAGCTATTGT TAAAGTAAAA TTTGATGCTA AAAAAGGCAA TGACATTTTG
    4451 TTTAAGCTTA CAACTAAAGA TGGAAAAACG CCCCCATTAG GAGCTATAGC
    4501 CCATGAAAAA AATGGAAAAC AGATTAATAC GGGTATCGTT GACGATGATG
    4551 GTATGCTTTA TATGTCTGGA TTATCAGGGA CAGGGATTAT TAATGTAACA
    4601 TGGAATGGAA AAGTCTGTTC ATTTCCTTTT TCAGAAAAAG ATATATCTAG
    4651 CAAACAATTA TCTGTTGTAA ATAAACAATG TTAGGTAGTG CATCCAATTA
    4701 GTAGAACATG TGTTTTTCGA TAAACGCTCC GATCTCTTTT TCGTGGATCT
    4751 CAACTGAGCG TGAGAAGCAG ATTGTTTTAC GAGCCAACCG CTTAATGCGG
    4801 GTGCGTAGCG TCAGATTATT ACGCTCAATG CGTTGGGTGA ATATTTTGCC
    4851 GGTCAGATGC TTATTCTTCG GTACC

    B. Cell Expression Clone
  • E. coli HB101 was purchased from the American Type Culture Collection, Manassas Va. It is ATCC #33694 and batch #91-1. (Escherichia coli ATCC 33694) Preceptrol® culture. D. Ish-Horowicz and J. F. Burke HB101 ←H. Boyer. Genotype: F-leuB6 proA2 recA13 thi-1 ara-14 lac YlgalK2 xyl-5 mtl-1 rpsL20 supE44 hsdS20 (r-B m-B at least thi-hsd from Escherichia coli B). Produces isoprene (Curr. Microbiol. 30:97-103, (1995), J. Mol. Biol. 41:459-472, (1969), Methods Enzymol. 68:245-267, (1979). Growth Conditions: Medium 1065 37° C.
  • The plasmid containing the CS6 genes, the pUC19 origin of replication, and the gene for kanamycin resistance was transferred into E. coli HB101 by transformation. Transformants were selected by growth on L agar supplemented with 0.04% Xgal with 50 μgm per ml kanamycin sulfate and/or 50 μgm per ml ampicillin.
  • One copy of the CS6 genes exists as an extrachromosomal plasmid of high (500-700) copy number. The CS6 genes are present on a plasmid, not integrated into the chromosome. The plasmid has been isolated from the strain and examined by agarose gel electrophoresis.
  • Plasmid DNA from E8775 tox− was transferred to laboratory strain DH5α as a cointegrate with F′lacts::Tn5, a conjugative plasmid. Transfer of the F′lacts::Tn5 plasmid was selected by antibiotic resistance to kanamycin and CS6 expression was detected by Western blot using polyclonal antisera specific for CS6. Plasmids were isolated and a cointegrate was identified based on the large size. A spontaneous derivative in which the F′lacts::Tn5 was removed was obtained and named M56. M56 contains a 61-megadalton plasmid from E8775 tox− and expresses CS6. Plasmid DNA from M56 was isolated, partially digested with restriction enzyme HindIII, and ligated to pUC19 that had been digested with HindIII. The ligation mixture was transformed into DH5α and plated onto L agar supplemented with ampicillin and X-gal. White (lac−) colonies were picked to CFA plates supplemented with ampicillin and tested for CS6 expression.
  • A stable clone named M233 with an insert of approximately 24 kb into the cloning site of pUC19 was obtained. It was a spontaneous deletion of a larger clone. Subclones were obtained by digestion with various enzymes and a subclone containing approximately 5 kb from the HindIII site to Kpnl site was found that expressed CS6. This clone was designated M285. Expression of CS6 was verified by transferring plasmids into E. coli strain HB101 and detecting CS6 expression. The cloned CS6 is expressed under the same conditions as CS6 from the native 61-megadalton plasmid: CS6 was detected in extracts from bacteria grown at 37° C. on CFA agar, L agar or MacConkey agar. CS6 was not expressed on bacteria grown at 17° C.
  • Studies were performed to determine appropriate handling of strain M285 for reproducible expression of CS6. Growth temperature was found to be especially important.
  • As indicated above, the protein sequence of the N-terminus of CS6 was determined from strains E8775 and from M233, the large clone derived from E8775. The 16 kDa proteins recovered from heat, saline extracts, and ammonium sulfate precipitation of M233 yielded two amino acids at each position (except cycle 12) indicating that two proteins were present. From the strength of the two signals, a probable primary sequence and a probable secondary sequence call was made for each of fifteen cycles. Quantitative analysis of the peak areas indicated that the molar ratio of the primary sequence (CS6A) to secondary sequence (CS6B) was approximately 3:1. The presence of the same two proteins was evident from strain E8775 grown on CFA agar and on L agar.
  • The DNA sequence of the DNA inserted into pUC19 in clone M285 was determined. Wim Gaastra's group in the Netherlands independently determined the DNA sequence of CS6 genes from ETEC strain E10703. The DNA sequences are available from Genebank accession numbers U04846 and U04844, respectively. A stretch of DNA of 4,219 base pairs was 98% identical. The DNA sequences diverge abruptly on both sides of the common region, defining the limits of the CS6 genes. Four open reading frames were detected within the common area. These were designated cssA, cssB, cssC, and cssD.
  • The four open reading frames are preceded by consensus sequences for binding RNA polymerase and ribosomes. The first open reading frame, cssA was identified as the gene for the CS6 structural protein designated as the primary protein based on the amino acid N-terminal sequence. The deduced molecular weight agrees with that previously determined from SDS PAGE. cssA includes a signal sequence that is typical for many exported proteins. Eleven of 136 residues differ between the deduced CssA proteins from E8775 and from E10704.
  • cssB begins 17 bases downstream from cssA. There is a typical signal sequence. cssB was identified as the gene for the CS6 structural protein designated as the secondary protein based on the amino acid N-terminal sequence. Five of 146 residues differ between the deduced CssA proteins from E8775 and from E10704.
  • A region of dyad symmetry is present 6 bases downstream from cssB in both clones. The sequence is GGCCGCATTATTGCGGCC (SEQ ID NO:2) in E8775 ETEC and GGCCGCATTATTGATTGCGGCC (SEQ ID NO:3) in E10703. Underlined bases form the G-C rich stem. The calculated free energy value of these structures is −14.8 kcal. Such structures are often found in fimbrial operons after the genes encoding structural proteins.
  • cssC begins 48 bases downstream from cssB. It has a typical signal sequence. The deduced proteins from both clones have 212 residues with 7 differences. A search of protein databases indicated CssC is homologous to chaperone proteins necessary for expression of a number of fimbriae. The structure of PapD, the chaperone protein for Pap fimbriae, has been solved by X-ray crystallography and regions important for conserving the structural domains have been identified. CssC conforms to this consensus.
  • The cssD gene begins 14 bases upstream of the end of cssC. The protein from E8775 is truncated relative to the protein from E10703 and there are 28 differences between CssD from E8775 and E10703. The deduced protein from cssD is homologous to molecular ushers. Overall, CssD and the other proteins are only around 30% identical and around 50% similar, but the nine proteins have areas of high homology dispersed throughout, especially the first 410 residues, and 4 cysteines (residues 91, 112, and two near the C-terminus) which are conserved in all ushers.
  • A region of dyad symmetry is present 347 base pairs into the cssD gene in both clones. The calculated free energy value of these structures is −7.2 kcal.
  • The plasmid from strain M285 was transformed into E. coli HB101 purchased from ATCC. The resulting strain was named M295. Expression of CS6 from M295 was achieved from small-scale fermentation. For production for human use, it was desirable to add a gene for resistance to kanamycin as the selectable marker. To that end, a vector was constructed based on pUC19 but with a gene for kanamycin resistance in place of the gene for ampicillin resistance. The CS6 genes from the pUC19 clone were subcloned into the new vector and transformed into E. coli HB101.
  • Vector pM323 was constructed as follows. The kanamycin resistance gene was purchased from Pharmacia, Uppsala, Sweden (KanR GenBlock®) and inserted into a cloning vector by Dr. David Lanar at WRAIR. DNA including the gene was amplified by PCR using the plasmid from Dr. Lanar as template and primers flanking the multiple cloning site. A product of the desired size (1,580 bp) was obtained, but with much template present. To increase the purity of the 1,580 fragment, a second PCR reaction was performed, this time with a small amount of the first PCR reaction as template. This product was confirmed by agarose gel electrophoresis, then digested with restriction enzyme HincII to remove unwanted restriction enzyme recognition sites. This product was ligated to pUC19 digested with Sspl. The ligation mix was transformed into E. coli DH5α and plated on L agar plates supplemented with kanamycin and Xgal. Isolate M318 had the desired phenotype of resistance to kanamycin and ampicillin with lacZ′ intact. The gene for ampicillin resistance was removed to make a smaller vector. This was achieved by designing and synthesizing 2 oligonucleotides to amplify just the portion of pM318 with the gene for kanamycin resistance, the lacZ′ gene carrying the multiple cloning site, and the origin of replication. PCR was performed, the product ligated then transformed into E. coli DH5α with selection on L agar plates supplemented with kanamycin and Xgal. Isolate M323 had the desired phenotype of resistance to kanamycin, sensitivity to ampicillin, and intact lacZ′. Restriction digest patterns confirmed the plasmid was a derivative of pUC19 with the gene for kanamycin resistance in place of the gene for ampicillin resistance.
  • The CS6 genes were cloned into vector pM323 from pM285. pM323 and pM285 were digested with restriction enzyme SstI, ligated, and transformed into E. coli DH5α with selection on L agar plates supplemented with kanamycin and Xgal. Isolate M334 was determined to express CS6. Plasmid analysis revealed M334 carried the CS6 genes and 2 copies of the vector. An attempt was made to remove one copy of vector and at the same time move the clone into HB101, the desired host strain for fermentation. Isolate M340 was determined to express CS6 and retained 2 copies of the vector. An isolated colony of M340 was shown to produce high amounts of CS6 and was saved as M346.
  • In another embodiment lacking the kanamycin resistance gene, clones from an ETEC strain of serotype O25:H42 were derived from E. coli E8775 which was originally isolated from samples from Bangladesh. E. coli M56, which contains a 61-megadalton plasmid from E8775 Tox− and expresses CS6 has been described. The host for cloning was E. coli DH5α which was purchased from Bethesda Research Laboratories, Inc., Gaithersburg, Md. The host for plasmids used for production of heat, saline extracts was HB101 (EMBO J. 4:3887-3893 (1985)).
  • Clones from E8775 were routinely grown in L broth. Antibiotics were added to L broth supplemented with agar as follows. Ampicillin was added, when appropriate, at 50 μg/ml. Chloramphenicol was used at 30 μg/ml. X-Gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside, Sigma) was added at 0.004%. CFA plates were prepared as previously described (Infect. Immun. 57:164-173 (1989)).
  • Cloning CS6 from E8775. The 61-megadalton plasmid from E. coli M56 was partially digested with Hindlll and ligated to pUC19 that had been digested with Hindlll. The ligation mixture was transformed into E. coli DH5α and plated onto L agar plates supplemented with ampicillin and X-gal. White (lac−) colonies were picked to CFA plates supplemented with ampicillin and tested for CS6 expression using antisera as described below. Plasmids were purified as described (Infect. Immun. 57:164-173 (1989)). Restriction enzymes were used according to the manufacturer's directions.
  • Detection of CS6 Expression. CS6 expression by bacterial colonies was detected after transfer to nitrocellulose and treatment as described by Mierendorf (Methods Enzymol. Methods Enzymol. 152:458-469 (1987)). Primary antisera was specific for CS6 and was raised in rabbits and absorbed as previously described (Infect. Immun. 57:164-173 (1989)), except that rabbits were inoculated intravenously with live bacteria suspended in normal saline. Secondary antibody was peroxidase-conjugated goat anti-rabbit IgG (Cappel Laboratories, Cochranville Pa.) and detection was by TMB Substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.).
  • Positive identification of CS6 was by western blots of heat, saline extracts. Heat, saline extracts were prepared from bacteria grown on the indicated media as described (Infect. Immun. 27:657-666 (1980)). Proteins were separated on precast 16% Tricine sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE, Novex Novel Experimental Technology, San Diego Calif.) and transferred to nitrocellulose. Blots were handled as described above for colony blots.
  • Determination of N-terminal sequence. Heat, saline extracts were obtained from E8775 or clones of E8775 grown on L agar or CFA. Partial purification of CS6 was obtained by ammonium sulfate precipitation, with extracts sequentially precipitated at 20%, 40%, then 60% saturation. Samples at 40% and 60% saturation were dialyzed against deionized water and loaded onto precast 16% Tricine SDS-PAGE (Novex, San Diego, Calif.). Proteins were blotted onto polyvinylidene difluoride (PVDF) membranes (Westrans, Schleicher & Schuell, Keene, N.H.), stained by Coomassie blue (Rapid Coomassie Stain, Diversified Biotech, Newton, Mass.) and bands of approximately 16 kDa were excised for automated gas-phase N-terminal sequencing analysis (Applied Biosystems Model 470A, Foster City, Calif.). Data were analyzed using the Model 610A Data Analysis Program, Version 1.2.1 (Applied Biosystems, Inc. Foster City, Calif.). These methods have been described in detail (Infect. Immun. 60:2174-2181 (1992)).
  • DNA sequencing. DNA sequencing of the clones derived from E8775 was performed using the Model 373A DNA sequencing system from Applied Biosystems, Inc, Foster City, Calif. Reactions were performed using the dideoxy method with fluorescent dye-labeled terminators, double-stranded templates, oligonucleotide primers, and AmpliTaq DNA polymerase following the manufacturer's protocol. Appropriate oligonucleotide primers were synthesized using a Model 391 DNA Synthesizer (Applied Biosystems, Inc, Foster City, Calif.). Plasmids were purified for use as templates by a slight modification of the alkaline lysis method and cesium chloride density gradient centrifugation described by Maniatis (MOLECULAR CLONING: A LABORATORY MANUAL Cold Spring Harbor Laboratory, Cold Spring Harbor (1982)). Plasmids were recovered by dialysis followed by multiple ethanol precipitations to remove residual salt. Sequence analysis was performed using software developed by the University of Wisconsin Genetics Computer Group (Nucleic Acids Res. 12:387-395 (1984)).
    • Results
  • CS6 genes cloned from ETEC strain E8775 into PUC19. A stable clone named M233 was obtained from a partial digest of the 61-megadalton plasmid from E. coli M56. It was a spontaneous deletion of a larger clone. The insert in M233 was approximately 24 kb. Subclones were obtained by digestion with various enzymes and a subclone containing 4.9 kb from the Hindlll site to Kpnl was found that expressed CS6. This clone was designated M285. Expression of CS6 was verified by transferring plasmids into E. coli HB 101 and detecting CS6 in heat, saline extracts. The cloned CS6 is expressed under the same conditions as CS6 from the native 61-megadalton plasmid (Table 1). CS6 was detected in western blots of heat, saline extracts of bacteria grown on CFA, L agar or MacConkey agar. CS6 was not expressed on bacteria grown at 17° C.
    TABLE 1
    Regulation of CS6 Expression
    Strain: M287 M56 E8775 HB101
    Plasmid: pM285 native native none
    Chromosome: HB101 HB101 native HB101
    Media — — — —
    CFA 37° C. + + + −
    CFA 17° C. − − − −
    L agar + + + −
    MacConkey + + + −
  • N-terminal sequence of CS6. The protein sequence of the N-terminus of CS6 was determined from strains E8775 and from M233, the large clone derived from E8775. The 16 kDa proteins recovered from heat, saline extracts, and ammonium sulfate precipitation of M233 yielded two amino acids at each position (except cycle 12) indicating that two proteins were present. From the strength of the two signals, a probable primary sequence and a probable secondary sequence call was made for each of fifteen cycles. Quantitative analysis of the peak areas indicated that the molar ratio of the primary sequence (CS6A) to secondary sequence (CS6B) was approximately 3:1. The presence of the same two proteins was evident from strain E8775 grown on CFA agar and on L agar.
  • DNA sequence of CS6 operons. The sequences of DNA cloned from E8775 (in M285) were determined. They are available from Genebank accession number U04846. The DNA sequence, when compared with sequences from another strain, were found to diverge abruptly on both sides of the common area. Four open reading frames were detected. These were designated cssA, cssB, cssC, and cssD for CS6.
  • The GC content of the DNA is 34% and the codon usage is in the range found for Escherichia coli genes that are expressed at low or very low levels as defined by Osawa et al. (Prokaryotic Genetic Code. Experentia 46:1097-1106 (1990)).
  • Genes encoding CS6 structural genes. The four open reading frames are preceded by consensus sequences for binding RNA polymerase and ribosomes. DNA and deduced amino acid sequence of css>A, a CS6 structural protein. The DNA sequence of the entire operon is available from Genebank accession number U04844. The deduced amino acid sequence from E8775 is given. The arrow indicates the site of cleavage of the signal peptide. The protein sequence is associated with the sequence for the second construct:
      −3S                   −1C                        RBS
    TTGACACATTACGAATCTTATGTATACAATAAAAATGATTATAGCAATATTAATGGTGTTAT
    ATGAAGAAAACAATTGGTTTAATTCTAATTCTTGCTTCATTCCCCAGCCATGCCAGAACA
    M  K  K  T  I  G  L  I  L  I  L  A  S  F  G  S  H  A  R  T 2
                                                         ↑
    GAAATAGCGACTAAAAACTTCCCAGTATCAACGACTATTTCAAAAAGTTTTTTTGCACCT
    E  I  A  T  K  N  P  P  V  S  T  T  I  S  K  5  F  F  A  P 22
    GAACCACGAATACAGCCTTCTTTTGGTGAAAATGTTGGAAAGGAAGGAGCTTTATTATTT
    E  P  R  I  Q  P  S  F  G  E  N  V  G  K  E  G  A  L  L  F 42
    AGTGTGAACTTAACTGTTCCTGAAAATGTATCCCAGGTAACGGTCTACCCTGTTTATCAT
    S  V  N  L  T  V  P  E  N  V  S  Q  V  T  V  Y  P  V  Y  D 62
    GAAGATTATGCCTTACCACGACTAGTAAATACCGCTGATGCTTCCCAATCAATAATCTAC
    E  D  Y  G  L  G  R  L  V  K  T  A  D  A  S  Q  S  I  I  Y 82
    CAGATTCTTCATGAGAAAGGGAAAAAAATGTTAAAAGATCATGGTGCAGACGTTACACCT
    Q  I  V  D  E  K  G  K  K  M  L  K  D  H  G  A  E  V  T  P 102
    AATCAACAAATAACTTTTAAAGCGCTGAATTATACTAGCGGGGAAAAAAAAATATCTCCT
    N  Q  Q  I  T  F  K  A  L  N  Y  T  S  C  E  K  K  I  S  P 122
    GGAATATATAACGATCACCTTATGGTTGGTTACTATGTAAACTAA (SEQ ID NO: 4)
    G  I  Y  N  D  Q  V  M  V  G  Y  Y  V  N  * (SEQ ID NO: 5) 136
  • The first open reading frame, cssA was identified as the gene for the CS6 structural protein CS6A designated as the primary protein based on the amino acid N-terminal sequence. cssA includes a signal sequence that is typical for many exported proteins. The deduced CssA protein from E8775 has 136 residues, as shown above and in Table 2. The molecular weight agrees with that previously determined from SDS PAGE. No homologous proteins were found by searching the protein databases, but conserved residues are present near the C-terminus and this is typical of fimbrial subunits that are carried across the periplasm by chaperons.
    TABLE 2
    Characteristics of Proteins Deduced from CS6 Operons
    Number of Molecular Isoelectric
    Protein Source Residues Weight Point
    CssA (CS6A) E8775 136 15,058 5.27
    CssB (CS6B) E8775 146 15,877 4.40
    CssC E8775 212 24,551 10.24
    CssD E8775 802 90,393 9.97
  • cssB begins 17 bases downstream from cssA. There is a typical signal sequence. cssB was identified as the gene for the CS6 structural protein CS6B designated as the secondary protein based on the amino acid N-terminal sequence. The C-terminus matches the consensus typical of fimbrial subunits. The sequence from E8775 is given. The arrow indicates the site of cleavage of the signal peptide.
    MLKKIISAIA LIAGTSGVVN A GNWQYKSLDV NVNIEQNFIP DIDSAVRIIP 30 (SEQ ID NO: 6)
                           ↑
    VNYDSDPKLD SQLYTVEMTI PAGVSAVKIA PTDSLTSSGQ QIGKLVNVNN 80
    PDQNMNYYIR KDSGAGNFMA GQKGSFPVKE NTSYTFSAIY TGGEYPMSGY 130
    SSGTYAGNLT VSFYSN 146
  • A region of dyad symmetry is present 6 bases downstream from cssB in both clones. The sequence is GGCCGCATTATTGCGGCC (SEQ ID NO:2) in E8775 ETEC. Underlined bases form the GC rich stem.
  • Genes with homology to fimbrial accessory proteins. cssC begins 48 bases downstream from cssB. It has a typical signal sequence. The deduced proteins from both clones have 212 residues with 7 differences. A search of protein databases indicated CssC is homologous to chaperone proteins necessary for expression of Pap, CS3, K88, K99, CS31A, S, and Type 1 fimbriae of E. coli and SEF14 of Salmonella enteritidis, F1 and pH6 antigen of Yersinia pestis, Type 3 of Klebsiella pneumoniae, Type b of Haemophilus influenzae Haemophilus influenzae, and filamentous heamagglutinin of Bordetella pertussis. The structure of PapD, the chaperone protein for Pap fimbriae, has been solved by X-ray crystallography and regions important for conserving the structural domains have been identified. CssC conforms to the following consensus. Below is the deduced amino acid sequence of cssC. The * indicates conservative amino acid replacements. Dots are gaps necessary for aligning all sequences. Boxes indicate β strands as defined for PapD. The designation of the β strands for domain 1 (A1 through G1) and domain 2 (A2-G2) are given below each box.
    Figure US20050025787A1-20050203-C00001
  • cssD begins 14 bases upstream of the end of cssC. When compared with a second sequence there are 28 differences between CssD from E8775 and the other sequence. The deduced protein from cssD is homologous to molecular ushers found in operons of Pap, CS3, K88, K99 and Type 1 fimbriae of E. coli and SEF14 of Salmonella enteritidis, F1 of Yersinia pestis, and Type 3 of Klebsiella pneumoniae. Overall, CssD and the other proteins are only around 30% identical and around 50% similar. Asterisks above the CssD sequences indicates amino acids conserved relative to molecular ushers.
                       *****  *  **         *    **
    MNQFYKKSHYSIQKHQITGLLFLLFIYPFSTSYGNEQFSFDSRFLPSGYN 50 (SEQ ID NO: 8)
        *  **G Y *** *N        * *       * C**   *  *
    YSLNSNLPPEGEYLVDIYINKIKKESAIIPFYIKGNKLVPCLSKEKISSL 100
    G* *   *  *C**   **   * **  * ** * **  *      * *
    GININNNDNTECVETSKAGISNISFEFSSLRLFIAVPKNLLSEIDKISSK 150
      * G* *********           ** * * ** * W**     *
    DIDNGIHALFFNYQVNTRLANNKNRYDYISVSPNINYFSWRLRNLFEFNQ 200
              ****** *      * *G* ***  ***   * G* * **
    NNDEKTWERNYTYLEKSFYDKKLNLVVGESYTNSNVYNNYSFTGISVSTD 250
      M       * * * **A *   * * *    *    V**G*F**
    TDMYTPSEIDYTPEIHGVADSDSQIIVRQGNTIIINESVPAGPFSFPITN 300
    *    * * * * *  *    * *    ****  **   * ** *
    LMYTGGQLNVEITDIYGNKKQYTVNNSSLPVMRKAGLMVYNFISGKLTKK 350
           *  *   *G     *****  *  **  *  G**  *G  G*
    NSEDGDFFTQGDINYGTHYNSTLFGGYQFSKNYFNLSTGIGTDLGFSGAW 400
     * ** *      *    *  *  *   *  * * * *    *  * ***
    LLHVSRSNFKNKNGYNINLQQNTQLRPFNAGVNFDYAYRKKRYVELSDIG 450
              ** * ****  *  * * *      Y*
    WHGNLYNQLKNSFSLSLSKSLNKYGNFSLDYNKMKYWDNAYDSNSMSIRY 500
                                 * ***P*      * *   **
    FFKFMRAMITTNCSLNKYQSYEKKDKRFSINISLPLTKDYGHISSNYSFS 550
           *      ** **   *  * * *                     *
    NANTGTATSSVGLNGSFFNDARLNWNIQQNRTTRNNGYTDNTSYIATSYA 600
       * * * **           * G ***   ** *    * * ***
    SPYGVFTGSYSGSNKYSSQFYSASGGIVLHSDGVAFTQKAGDTSALVRID 650
          *   * * *   G **   *  *  * * **   **    *
    NISDIKIGNTPGVYTGYNGFALIPHLQPFKKNTILINDKGIPDGITLANI 700
       **** ****   *    *   ** *   **  ****  *
    KKQVIPSRGAIVKVKFDAKKGNDILFKLTTKDGKTPPLGAIAHEKNGKQI 750
      ****   * *         * * *    C         *
    NTGIVDDDGMLYMSGLSGTGIINVTWNGKVCSFPFSEKDISSKQLSVVNK 800
     C
    QC 802
  • But comparison with the protein from another strain, the sequence data shows the proteins have areas of high homology dispersed throughout, especially the first 410 residues. CssD has 4 cysteines (residues 91, 112, and two near the C-terminus) which are conserved in all ushers.
  • A region of dyad symmetry is present 347 base pairs into the cssD gene in both clones. The calculated free energy value of these structures is −7.2 kcal.
  • DNA flanking the CS6 genes. When compared with another strain, the DNA sequences of the two clones diverge immediately Idownstream of cssD and 96 bases upstream of cssA. The non-homologous flanking regions have homology with five distinct insertion sequences. The homologies include 3% to 32% of each insertion sequence but not entire insertion sequences. The homology of and Iso-ISI in E8775 continues beyond the clones we have sequenced and may be a complete insertion sequences in the native plasmids.
  • It should be noted that minor variation in bases of the peptides does not destroy antigenicity. A protein having at least 60% homology with the CS6 A and B proteins identified herein having conservative substitution would be expected to have desirable properties.
  • As indicated previously, bacteria transformed with plasmids which express the CS6-A and CS6-B proteins may be administered by mouth. If the transformed bacteria are attenuated strains, they may be delivered live. It is also possible to administer killed bacteria. Carbonated beverages such as carbonated water are particularly useful as carriers which are inexpensive. When the bacteria are administered in a carrier wherein the pH is not over 7, an antacid may be given with the bacteria.
  • The CS6 A and CS6 B proteins may also be at least partially purified and administered by mouth by means usually used in the art to deliver antigens to the intestinal tract, including in protected forms such as liposomes, microcrystals, microdroplets, as microencapsulated formulations or as enterically coated capsules.

Claims (10)

1. A method of inducing, in a susceptible host, the production of antibodies against CS6 protein comprising administration of a composition of matter comprising a bacteria transformed with a plasmid which contains genes cssA and cssB, all of the cssC and DNA sequence of cssD which encodes at least 802 amino acids (at least 2406 base pairs), an origin of replication, a Lac promotor, and a kanamycin resistance gene wherein said bacteria expresses both CS6A and CS6B proteins.
2. A method of claim 1 wherein the bacteria are in a pharmaceutically acceptable carrier.
3. A method of claim 2 wherein the carrier is a carbonated liquid.
4. A protein containing the amino acid sequence
RTEIATKNFPVSTTISKSFFA PEPRIQPSFGENVGKEGALLF SVNLTVPENVSQVTVYPVYDE DYGLGRLVNTADASQSIIYQI VDEKGKKMLKDHGAEVTPNQQ ITFKALNYTSGEKKISPGIYN DQVMVGYYVN.
5. A composition of matter comprising a protein of claim 4 in a pharmaceutically acceptable carrier.
6. A bacteria transformed with a plasmid which contains genes cssA and cssB, all of the cssC and DNA sequence of cssD which encodes at least 802 amino acids (at least 2406 base pairs), an origin of replication, a Lac promotor, and a kanamycin resistance gene wherein said bacteria expresses both CS6A and CS6B proteins.
7. A composition of matter comprising bacteria of claim 6 in a pharmaceutically acceptable carrier.
8. A composition of matter comprising the bacteria of claim 6 wherein the carrier is a carbonated beverage.
9. A bacteria of claim 6 containing the sequence:
1 AAGCTTGTAA CCAGTTGATA AAAATATATC ACGCTGGGAA TGACGTGATG (Sequence ID No #1) 51 TATATACGGA GCAGCTATGT CGGAACAGAT ATTTTCCTAT CGGTATGCGT 101 TGTGAGTAAG CGTAAAGCCA ATGCTGTCTG TAACTCCTGA TCCTTGCAGA 151 CTAAATTAGA GCTCCTTCTA AATTAGACGG ATGGATAAAC CTACAGACTG 201 GCGCTCTGGG TCTCGCCGGA TATTTTCTAA TGAATTTAAG CTTCATATGG 251 TTGAACTGGC TTCGAAACCA AATGCCAATG TCGCACAACT GGCTCGGGAA 301 CATGGCGTTG ATAACAACCT GATTTTTAAA TAGCTACGCC TCTGGCAAAG 351 AGAAGGACGT ATTTCTCGTA GAATGCCTCC AACTATTGTA GGCCCTACAG 401 TACCACTGAG GTAGCCTGAA TTTAAAGCCG AAGCGGTCAG AACTGTTCTT 451 GGTGTGAACG TAGCACTCAC CAATAAAAGC ATCAATACGG TGCTCTGTTG 501 ACACATTACG AATGTTATGT ATACAATAAA AATGATTATA GCAATATTAA 551 TGGTGTTATA TGAAGAAAAC AATTGGTTTA ATTCTAATTC TTGCTTCATT 601 CGGCAGCCAT GCCAGAACAG AAATAGCGAC TAAAAACTTC CCAGTATCAA 651 CGACTATTTC AAAAAGTTTT TTTGCACCTG AACCACGAAT ACAGCCTTCT 701 TTTGGTGAAA ATGTTGGAAA GGAAGGAGCT TTATTATTTA GTGTGAACTT 751 AACTGTTCCT GAAAATGTAT CCCAGGTAAC GGTCTACCCT GTTTATGATG 801 AAGATTATGG GTTAGGACGA CTAGTAAATA CCGCTGATGC TTCCCAATCA 851 ATAATCTACC AGATTGTTGA TGAGAAAGGG AAAAAAATGT TAAAAGATCA 901 TGGTGCAGAG GTTACACCTA ATCAACAAAT AACTTTTAAA GCGCTGAATT 951 ATACTAGCGG GGAAAAAAAA ATATCTCCTG GAATATATAA CGATCAGGTT 1001 ATGGTTGGTT ACTATGTAAA CTAAATACTG GAAGTATGAT TATGTTGAAA 1051 AAAATTATTT CGGCTATTGC ATTAATTGCA GGAACTTCCG GAGTGGTAAA 1101 TGCAGGAAAC TGGCAATATA AATCTCTGGA TGTAAATGTA AATATTGAGC 1151 AAAATTTTAT TCCAGATATT GATTCCGCTG TTCGTATAAT ACCTGTTAAT 1201 TACGATTCGG ACCCGAAACT GGATTCACAG TTATATACGG TTGAGATGAC 1251 GATCCCTGCA GGTGTAAGCG CAGTTAAAAT CGCACCAACA GATAGTCTGA 1301 CATCTTCTGG ACAGCAGATC GGAAAGCTGG TTAATGTAAA CAATCCAGAT 1351 CAAAATATGA ATTATTATAT CAGAAAGGAT TCTGGCGCTG GTAACTTTAT 1401 GGCAGGACAA AAAGGATCCT TTCCTGTCAA AGAGAATACG TCATACACAT 1451 TCTCAGCAAT TTATACTGGT GGCGAATACC CTAATAGCGG ATATTCGTCT 1501 GGTACTTATG CAGGAAATTT GACTGTATCA TTTTACAGCA ATTAAAAAAA 1551 GGCCGCATTA TTGCGGCCAT TGACGATACT GCTAGGCAAA AATATGAAAT 1601 CAAAGTTAAT TATACTATTG ACGTTAGTGC CATTTTCATC TTTTTCAACA 1651 GGAAATAATT TTGAAATAAA TAAGACACGA GTAATTTACT CTGACAGCAC 1701 ACCATCAGTT CAAATATCAA ATAATAAAGC ATATCCTTTA ATTATTCAAA 1751 GCAATGTATG GGATGAAAGC AATAATAAAA ATCATGACTT TATAGCAACA 1801 CCACCGATTT TTAAAATGGA AAGTGAAAGT CGGAATATAA TAAAAATAAT 1851 TAAAACAACT ATTAATTTGC CGGACTCTCA GGAAAGTATG AGATGGTTAT 1901 GTATTGAATC AATGCCACCA ATAGAAAAAA GTACTAAAAT AAACAGAAAA 1951 GAAGGAAGGA CAGACAGTAT TAATATCAGC ATTCGGGGGT GCATTAAACT 2001 GATATATCGA CCTGCCAGTG TTCCGTCTCC TGTTTTTAAT AATATAGTAG 2051 AAAAATTAAA ATGGCATAAA AATGGAAAGT ATCTTGTATT AAAAAATAAT 2101 ACACCCTATT ACATTAGCTT TTCTGAGGTT TTTTTTGATT CAGATAAAGT 2151 AAACAATGCA AAAGATATTT TATATGTAAA ACCATACTCA GAGAAGAAAA 2201 TAGATATCAG CAACAGAATA ATAAAAAAAA TCAAATGGGC TATGATTGAT 2251 GATGCTGGCG CAAAAACAAA ACTTTATGAA TCAATTTTAT AAAAAATCTC 2301 ATTACAGTAT ACAAAAACAT CAGATTACAG GCTTGCTTTT TTTGCTATTT 2351 ATATATCCTT TCTCAACCTC ATATGGAAAT GAACAATTTA GTTTTGACTC 2401 ACGATTCCTA CCATCAGGTT ATAATTACTC TTTAAATAGT AACTTACCTC 2451 CTGAAGGTGA GTATCTGGTT GATATTTATA TTAACAAAAT AAAAAAGGAG 2501 TCCGCGATTA TTCCTTTTTA TATAAAAGGA AATAAACTTG TACCATGTTT 2551 ATCAAAAGAA AAAATTTCAT CTTTGGGTAT CAACATTAAT AATAACGACA 2601 ACACAGAGTG TGTAGAAACA AGTAAGGCAG GTATTAGTAA TATCAGCTTT 2651 GAGTTTAGCT CTCTTCGTTT GTTTATTGCT GTACCGAAAA ATCTTCTGTC 2701 TGAGATTGAT AAAATATCAT CAAAGGATAT AGATAACGGG ATTCATGCTT 2751 TATTTTTTAA TTATCAAGTA AATACAAGGC TAGCCAATAA TAAAAATCGT 2801 TATGATTACA TTTCTGTTTC ACCAAATATA AATTATTTTT CATGGCGGTT 2851 GCGTAATCTT TTTGAATTTA ACCAAAACAA CGATGAAAAA ACATGGGAAA 2901 GAAACTACAC TTATCTAGAA AAAAGTTTTT ATGATAAAAA GCTAAACTTA 2951 GTCGTTGGTG AAAGTTATAC GAATTCAAAT GTTTATAATA ACTACTCTTT 3001 TACTGGTATT TCAGTTTCTA CAGATACAGA TATGTATACG CCAAGTGAAA 3051 TCGATTATAC ACCAGAAATT CATGGAGTGG CTGATTCAGA CTCTCAGATT 3101 ATTGTCAGGC AAGGCAACAC CATTATCATT AATGAAAGTG TTCCAGCCGG 3151 ACCGTTCTCA TTTCCAATAA CCAATCTCAT GTATACTGGG GGGCAACTTA 3201 ATGTGGAGAT AACAGATATT TATGGAAATA AAAAACAATA TACTGTCAAT 3251 AATTCCTCTC TTCCTGTTAT GAGAAAAGCG GGACTAATGG TATATAATTT 3301 TATATCTGGG AAATTAACAA AAAAAAATAG TGAGGATGGT GATTTTTTTA 3351 CTCAAGGTGA TATTAACTAC GGTACTCACT ATAACAGCAC ACTATTCGGT 3401 GGATATCAGT TTAGTAAAAA TTATTTTAAC TTATCTACTG GTATAGGCAC 3451 TGATCTGGGA TTTTCTGGAG CATGGCTACT ACACGTTAGC AGAAGTAATT 3501 TTAAGAATAA AAATGGATAT AATATTAATC TACAACAAAA CACTCAGTTA 3551 AGACCATTCA ATGCCGGGGT TAATTTCGAT TACGCATACA GAAAAAAAAG 3601 GTATGTGGAA CTTTCCGACA TTGGCTGGCA TGGTAATTTA TATAATCAAC 3651 TTAAAAATAG TTTTTCTTTA TCCTTGTCAA AATCATTGAA TAAATACGGA 3701 AATTTCTCAC TTGATTATAA CAAAATGAAA TACTGGGATA ATGCGTATGA 3751 TAGTAACTCA ATGTCGATTC GTTATTTTTT TAAATTCATG CGAGCAATGA 3801 TTACAACAAA TTGTTCTTTA AATAAATATC AATCTTATGA AAAAAAAGAT 3851 AAAAGATTTA GTATTAATAT ATCATTGCCT TTAACCAAAG ATTACGGGCA 3901 CATATCTTCA AACTATTCAT TTTCCAATGC AAATACACGA ACGGCAACCA 3951 GTTCTGTAGG CTTAAACGGT AGTTTTTTTA ATGACGCAAG ATTAAACTGG 4001 AACATTCAGC AGAACAGAAC GACCCGTAAC AATGGATATA CTGATAATAC 4051 CAGTTACATA GCAACCAGCT ATGCCTCTCC CTATGGCGTT TTTACTGGTT 4101 CATATTCAGG ATCGAACAAG TATTCAAGCC AGTTTTATTC TGCATCGGGA 4151 GGTATTGTTT TGCATAGCGA TGGCGTAGCT TTTACTCAAA AAGCCGGAGA 4201 TACCTCTGCT CTTGTCCGTA TTGATAATAT TTCTGATATA AAAATTGGTA 4251 ACACTCCTGG TGTTTATACT GGGTATAATG GTTTTGCTTT AATTCCTCAT 4301 CTTCAGCCGT TCAAAAAAAA CACCATTTTA ATTAATGATA AAGGAATTCC 4351 AGACGGTATT ACTCTTGCTA ATATAAAAAA ACAAGTTATC CCATCACGAG 4401 GAGCTATTGT TAAAGTAAAA TTTGATGCTA AAAAAGGCAA TGACATTTTG 4451 TTTAAGCTTA CAACTAAAGA TGGAAAAACG CCCCCATTAG GAGCTATAGC 4501 CCATGAAAAA AATGGAAAAC AGATTAATAC GGGTATCGTT GACGATGATG 4551 GTATGCTTTA TATGTCTGGA TTATCAGGGA CAGGGATTAT TAATGTAACA 4601 TGGAATGGAA AAGTCTGTTC ATTTCCTTTT TCAGAAAAAG ATATATCTAG 4651 CAAACAATTA TCTGTTGTAA ATAAACAATG TTAGGTAGTG CATCCAATTA 4701 GTAGAACATG TGTTTTTCGA TAAACGCTCC GATCTCTTTT TCGTGGATCT 4751 CAACTGAGCG TGAGAAGCAG ATTGTTTTAC GAGCCAACCG CTTAATGCGG 4801 GTGCGTAGCG TCAGATTATT ACGCTCAATG CGTTGGGTGA ATATTTTGCC 4851 GGTCAGATGC TTATTCTTCG GTACC
10. A protein expressed by the bacteria of claim 6 containing the sequence:
RTEIATKNFPVSTTISKSFFA (SEQ. ID No. 9) PEPRIQPSFGENVGKEGALLF SVNLTVPENVSQVTVYPVYDE DYGLGRLVNTADASQSIIYQI VDEKGKKMLKDHGAEVTPNQQ ITFKALNYTSGEKKISPGIYN DQVMVGYYVN.
US10/754,641 1994-05-13 2004-01-12 Transformed bacteria producing CS6 antigens as vaccines Abandoned US20050025787A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/754,641 US20050025787A1 (en) 1994-05-13 2004-01-12 Transformed bacteria producing CS6 antigens as vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24348294A 1994-05-13 1994-05-13
US78814597A 1997-01-24 1997-01-24
US09/479,877 US7118758B1 (en) 1997-01-24 2000-01-10 Transformed bacteria producing CS6 antigens as vaccines
US10/754,641 US20050025787A1 (en) 1994-05-13 2004-01-12 Transformed bacteria producing CS6 antigens as vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/479,877 Division US7118758B1 (en) 1994-05-13 2000-01-10 Transformed bacteria producing CS6 antigens as vaccines

Publications (1)

Publication Number Publication Date
US20050025787A1 true US20050025787A1 (en) 2005-02-03

Family

ID=37072380

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/479,877 Expired - Lifetime US7118758B1 (en) 1994-05-13 2000-01-10 Transformed bacteria producing CS6 antigens as vaccines
US10/754,641 Abandoned US20050025787A1 (en) 1994-05-13 2004-01-12 Transformed bacteria producing CS6 antigens as vaccines
US10/768,093 Expired - Fee Related US7332172B2 (en) 1994-05-13 2004-02-02 Transformed bacteria producing CS6 antigens as vaccines
US11/682,648 Expired - Fee Related US7625571B2 (en) 1994-05-13 2007-03-06 Transformed bacteria producing CS6 antigens as vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/479,877 Expired - Lifetime US7118758B1 (en) 1994-05-13 2000-01-10 Transformed bacteria producing CS6 antigens as vaccines

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/768,093 Expired - Fee Related US7332172B2 (en) 1994-05-13 2004-02-02 Transformed bacteria producing CS6 antigens as vaccines
US11/682,648 Expired - Fee Related US7625571B2 (en) 1994-05-13 2007-03-06 Transformed bacteria producing CS6 antigens as vaccines

Country Status (1)

Country Link
US (4) US7118758B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625571B2 (en) * 1994-05-13 2009-12-01 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102546A1 (en) * 1998-02-12 2002-08-01 Nolan Lisa K. Nucleic acid encoding an avian E.coli iss polypeptide and methods of use
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
CA2477273A1 (en) * 2002-02-25 2003-09-18 U.S. Army Medical Research And Materiel Command Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
EP1981536A4 (en) * 2006-02-01 2012-03-14 Gotovax Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
BRPI0813428A2 (en) * 2007-07-02 2014-12-23 Crucell Sweden Ab RECOMBINANT OPERA, METHOD FOR PRODUCING A HOST CELL, COMPOSITION OF DIARRHEA VACCINE, AND USE OF AN OPERA
WO2014047625A1 (en) * 2012-09-24 2014-03-27 Montana State University Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
JP6403680B2 (en) * 2012-11-19 2018-10-10 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ Recombinant polypeptide constructs containing multiple toxigenic E. coli pilus subunits
AU2015342943B2 (en) 2014-11-05 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4756919A (en) * 1982-06-18 1988-07-12 Thomas J. Lipton Acid preservation systems for food products
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US5686079A (en) * 1988-09-06 1997-11-11 Washington University Oral immunization by transgenic plants
US5698416A (en) * 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
US5935838A (en) * 1994-06-03 1999-08-10 Sbl Vaccin Ab Method of cultivating bacteria proteins that are expressed in a temperature regulated manner
US6558678B1 (en) * 1991-02-26 2003-05-06 Jan Holmgren Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans
US20030198992A1 (en) * 1993-11-18 2003-10-23 Scott Hultgren Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6844010B1 (en) * 1984-03-16 2005-01-18 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
US20050074813A1 (en) * 1993-05-21 2005-04-07 Jeffrey Nauss Model for testing immunogenicity of peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761372A (en) * 1981-01-12 1988-08-02 New York University Mutant enterotoxin of E. coli
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5017372A (en) * 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
US5874088A (en) * 1992-07-06 1999-02-23 President And Fellows Of Harvard College Deletion mutants of cholera vaccines expressing heterologous antigens
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US8558678B2 (en) 2010-02-25 2013-10-15 Ford Global Technologies, Llc Method and systems for detecting an unauthorized use of a vehicle by an authorized driver

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4756919A (en) * 1982-06-18 1988-07-12 Thomas J. Lipton Acid preservation systems for food products
US6844010B1 (en) * 1984-03-16 2005-01-18 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5686079A (en) * 1988-09-06 1997-11-11 Washington University Oral immunization by transgenic plants
US6558678B1 (en) * 1991-02-26 2003-05-06 Jan Holmgren Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans
US20050074813A1 (en) * 1993-05-21 2005-04-07 Jeffrey Nauss Model for testing immunogenicity of peptides
US6939546B2 (en) * 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US20030198992A1 (en) * 1993-11-18 2003-10-23 Scott Hultgren Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US5935838A (en) * 1994-06-03 1999-08-10 Sbl Vaccin Ab Method of cultivating bacteria proteins that are expressed in a temperature regulated manner
US5698416A (en) * 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625571B2 (en) * 1994-05-13 2009-12-01 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines

Also Published As

Publication number Publication date
US7332172B2 (en) 2008-02-19
US7118758B1 (en) 2006-10-10
US7625571B2 (en) 2009-12-01
US20040156829A1 (en) 2004-08-12
US20080038319A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
US7625571B2 (en) Transformed bacteria producing CS6 antigens as vaccines
US10035826B2 (en) Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
Sokolovic et al. Synthesis of species-specific stress proteins by virulent strains of Listeria monocytogenes
US20050260223A1 (en) Salmonella vaccine materials and methods
Abe et al. Characterization of two virulence proteins secreted by rabbit enteropathogenic Escherichia coli, EspA and EspB, whose maximal expression is sensitive to host body temperature
US20110200638A1 (en) Bacterial vaccine
Guerry et al. Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines
Cárdenas et al. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors
JP6329544B2 (en) New live attenuated Shigella vaccine
JP2007289194A (en) Vacuolating toxin-deficient h. pylori and related method
AU2001256957A1 (en) Salmonella vaccine materials and methods
Froehlich et al. CooC and CooD are required for assembly of CS1 pili
AU2002321644A1 (en) Bacterial vaccine
EP0892054B1 (en) Clostridium perfringens vaccine
EP1443959A1 (en) Salmonella vaccine
US5525504A (en) Cytolysin gene and gene product
Elkins et al. Cloning and constitutive expression of structural genes encoding gonococcal porin protein in Escherichia coli and attenuated Salmonella typhimurium vaccine strains
Williamson et al. Identification of proteins expressed by the essential virulence region of the Salmonella dublin plasmid
WO2003087147A1 (en) Stretptococcal genes involved in osmotic and oxidative stress and in virulence
EP1640013A2 (en) Inactivated Salmonella vaccines
WO1995004133A1 (en) Production of gonorrheal pi proteins and vaccines in e. coli and salmonella
AU2002223922A1 (en) Salmonella vaccine

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION